SynthesisCancer metastasis reviews2026
Immunological and antitumor responses to HPV-targeted therapeutic vaccines in preclinical models of head and neck cancer: a systematic review.
Synthesis in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is increasingly prevalent and accounts for 22-70% of HNSCCs depending on the region. Although prophylactic HPV vaccines were approved in the early 2000s to prevent HPV infection and oncogenesis, they are ineffective against established HPV infections and related cancers. The standard of care for these HPV-associated oropharyngeal cancers combines radiotherapy, surgery, and chemotherapy. However, these treatments can result in significant lifelong side effects for patients with no new treatments entering regular clinical practice in the past decade. Therapeutic cancer vaccines represent an opportunity for novel treatment approaches in HPV-associated cancer, particularly because these cancers display viral tumor-specific antigens (TSAs) such as E6 and E7, making them easily targetable by this type of immunotherapy. Currently, there are no FDA-approved therapeutic vaccines for HPV-associated cancers, but preclinical and clinical studies are ongoing in this area. In this systematic review, we describe current HPV vaccination strategies, their biological mechanisms, and their immunological and therapeutic effects in preclinical cancer models. We discuss each component of therapeutic vaccines: antigens, delivery platforms, adjuvants, and combination agents. We also assess the results of recent preclinical studies evaluating HPV therapeutic vaccines to provide an outlook on the future of this treatment modality.
Indexed as
Identifiers
42550292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.